Maurer A H, Krevsky B, Knight L C, Brown K
Department of Diagnostic Imaging, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.
J Nucl Med. 1996 May;37(5):818-22.
We studied the effects of several drugs on gastrointestinal transit (tramadol HCl, acetaminophen with codeine and placebo) in a randomized, double-blind, crossover study.
Combined gastric emptying, small bowel and colonic transit scintigraphy was performed in 12 normal subjects. Each subject received a standardized diet and study drug on Days 1-5. On Day three, subjects received a radiolabeled solid and liquid phase meal.
No significant difference in the gastric T1/2 (mean +/- s.e.m.) of solids for placebo (69 +/- 7 min), APAP/C (74 +/- 15 min) or tramadol (686 +/- 8 min) (p = 0.86) were seen. Similarly there was no significant difference in the T1/2 of liquids for placebo (31 +/- 4 min), APAP/C (41 +/- 6 min) (p = 0.29). Orocecal transit times were not significantly different for placebo (237 +/- 20 min), APAP/C (311 +/- 26 min) or tramadol (311 +/- 10 min) (p = 0.12). Colon geometric centers (GC) for placebo at 24, 48 and 72 hr were 4.6 +/- 0.35, 6.0 +/- 0.28 and 6.8 +/- 0.08. The GC for tramadol and APAP/C were all significantly lower at 72 hr, 6.4 +/- 0.17 and 6.2 +/- 0.17, respectively compared to the placebo. The GC of tramadol at 24 and 48 hr (3.8 +/- 0.4, 5.4 +/- 0.26) were not significantly different from placebo. In contrast, the GC for APAP/C at 24 and 48 hr (3.3 +/- 0.31, 5.0 +/- 0.26) were significantly delayed. All subjects recorded a significant increase in constipation on drugs compared to placebo (p = 0.04).
Tramadol and APAP/C had no effect on gastric emptying or small bowel transit. At equianalgesic doses, tramadol caused less delay in colonic transit than APAP/C for 48 hr and delay in the GC agreed with the subjective complaints of constipation on both drugs.
在一项随机、双盲、交叉研究中,我们研究了几种药物(盐酸曲马多、对乙酰氨基酚可待因和安慰剂)对胃肠转运的影响。
对12名正常受试者进行了胃排空、小肠和结肠转运闪烁扫描联合检查。每位受试者在第1 - 5天接受标准化饮食和研究药物。在第3天,受试者接受放射性标记的固体和液体餐。
安慰剂组(69±7分钟)、对乙酰氨基酚/可待因组(74±15分钟)或曲马多组(686±8分钟)固体的胃T1/2(平均值±标准误)无显著差异(p = 0.86)。同样,安慰剂组(31±4分钟)、对乙酰氨基酚/可待因组(41±6分钟)液体的T1/2也无显著差异(p = 0.29)。安慰剂组(237±20分钟)、对乙酰氨基酚/可待因组(311±26分钟)或曲马多组(311±10分钟)的口盲肠转运时间无显著差异(p = 0.12)。安慰剂组在24、48和72小时的结肠几何中心(GC)分别为4.6±0.35、6.0±0.28和6.8±0.08。与安慰剂相比,曲马多组和对乙酰氨基酚/可待因组在72小时的GC均显著降低,分别为6.4±0.17和6.2±0.17。曲马多组在24和48小时的GC(3.8±0.4,5.4±0.26)与安慰剂无显著差异。相比之下,对乙酰氨基酚/可待因组在24和48小时的GC(3.3±0.31,5.0±0.26)显著延迟。与安慰剂相比,所有受试者在服用药物后便秘均显著增加(p = 0.04)。
曲马多和对乙酰氨基酚/可待因对胃排空或小肠转运无影响。在等效镇痛剂量下,曲马多在48小时内引起的结肠转运延迟比乙酰氨基酚/可待因少,并且结肠几何中心的延迟与两种药物引起便秘的主观主诉一致。